Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted … – Business Wire (press release)
|
Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR–T Cell Therapy Has Been Granted …
Business Wire (press release) SUMMIT, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) and bluebird bio, Inc. (NASDAQ:BLUE) today announced that bb2121, a chimeric antigen receptor T–cell (CAR-T) therapy targeting b-cell maturation antigen … |
